非酒精性脂肪性肝病发病机制及治疗进展

被引：20

作者：

李丹

李异玲

机构：

[1] 中国医科大学附属第一医院

来源：

实用药物与临床 | 2017年 / 20卷 / 11期

关键词：

非酒精性脂肪性肝病; 降脂药; 胰岛素抵抗;

D O I：

10.14053/j.cnki.ppcr.201711029

中图分类号：

R575.5 [肝代谢障碍];

学科分类号：

1002 ; 100201 ;

摘要：

近年来,非酒精性脂肪性肝病(Nonalcoholic fatty liver disease,NAFLD)发病率在世界范围内逐渐上升,在我国是仅次于病毒性肝炎、酒精性脂肪性肝病的导致肝硬化的主要病因之一。其发病机制尚不清楚,目前较为公认的机制为"二次打击"学说,第一次打击为胰岛素抵抗,脂质代谢紊乱导致肝细胞内脂质过度沉积,三酰甘油增多;第二次打击是肝细胞内氧化应激及脂质过氧化,是发展为NASH、肝硬化甚至肝癌的关键。近年来,对胰岛素增敏剂治疗NAFLD的研究较多,而关于降脂药的研究则少见。本综述从NAFLD的概述、发病机理、降血脂药的作用等方面进行阐述。

引用

页码：1340 / 1343

页数：4

共 22 条

[1] Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds [J].

Xu, Chengfu ;

Wan, Xingyong ;

Xu, Lei ;

Weng, Honglei ;

Yan, Ming ;

Miao, Min ;

Sun, Yan ;

Xu, Genyun ;

Dooley, Steven ;

Li, Youming ;

Yu, Chaohui .

JOURNAL OF HEPATOLOGY, 2015, 62 (06) :1412-1419

[2] The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Diehl, Anna Mae ;

Brunt, Elizabeth M. ;

Cusi, Kenneth ;

Charlton, Michael ;

Sanyal, Arun J. .

GASTROENTEROLOGY, 2012, 142 (07) :1592-1609

[3] Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies [J].

Nseir, William ;

Mograbi, Julnar ;

Ghali, Murad .

DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (07) :1773-1781

[4] Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010 [J].

Fan, Jian Gao ;

Jia, Ji Dong ;

Li, You Ming ;

Wang, Bing Yuan ;

Lu, Lun Gen ;

Shi, Jun Pin ;

Chan, Lik Yuen .

JOURNAL OF DIGESTIVE DISEASES, 2011, 12 (01) :38-44

[5] A position statement on NAFLD/NASH based on the EASL 2009 special conference [J].

Ratziu, Vlad ;

Bellentani, Stefano ;

Cortez-Pinto, Helena ;

Day, Chris ;

Marchesini, Giulio .

JOURNAL OF HEPATOLOGY, 2010, 53 (02) :372-384

[6]

Kupffer cells promote hepatic steatosis via interleukin‐1β–dependent suppression of peroxisome proliferator‐activated receptor α activity.[J].Rinke Stienstra;Fredy Saudale;Caroline Duval;Shohreh Keshtkar;Johanna E. M. Groener;Nico van Rooijen;Bart Staels;Sander Kersten;Michael Müller.Hepatology.2010, 2

[7] Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease [J].